Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
09/25/20 10:41 PM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Sep 15 2020
Summary ToggleAdverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science
- Sep 10 2020
Summary ToggleAdverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference
- Aug 18 2020
Summary ToggleAdverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock
- Aug 12 2020
Summary ToggleAdverum Biotechnologies Announces Pricing of Public Offering of Common Stock
There are currently no events to display.